WallStSmart
PDSB

PDS Biotechnology Corp

NASDAQ: PDSB · HEALTHCARE · BIOTECHNOLOGY

$1.30
+12.96% today

Updated 2026-06-04

Market cap
$57.49M
P/E ratio
P/S ratio
EPS (TTM)
$-0.68
Dividend yield
52W range
$1 – $2
Volume
1.1M

WallStSmart proprietary scores

16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.0
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
2/9
Piotroski F-Score
Weak
-12.2
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$7.50
+476.92%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -12.23 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.37B
- Debt/equity 4.07x — high leverage

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-40.85M$-42.94M$-37.61M$-34.50M$-7.35M
EPS$-0.68
Free cash flow$-25.71M$-33.64M$-35.06M$-27.75B$-4.37B
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PDSB$57.49M164.33.05.04.0Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

PDS Biotechnology Corp trades at $1.30. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -12.23, it sits in the distress.

Frequently asked questions

What is PDS Biotechnology Corp's stock price?

PDS Biotechnology Corp (PDSB) trades at $1.30.

Is PDS Biotechnology Corp overvalued?

PDS Biotechnology Corp carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of PDS Biotechnology Corp (PDSB)?

The 12-month analyst consensus target is $7.50, about 476.9% above the current $1.30. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

PDS Biotechnology Corp's Altman Z-Score is -12.23, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-856.89%
Beta1.56
50D MA$1.06
200D MA$0.94
Shares out0.06B
Float0.05B
Short ratio
Avg volume1.1M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years